NOTE

Synthesis of New DOPA Derivative from L-Tyrosine for Construction of Bioactive Compound

DEQUN SUN^{1,*}, PEIHONG WAN¹, GUOQING ZHANG² and MIN LUO¹

¹Marine College, Shandong University (Weihai), No. 180, Wenhua West Road, Weihai 264209, P.R. China

²Institute of microbiology, Chinese Academy of Sciences, Beijing 100101, P.R. China

*Corresponding author: E-mail: dequn.sun@sdu.edu.cn

(Received: 3 December 2012;

Accepted: 27 September 2013)

AJC-14189

A practical synthetic method of new DOPA derivative was developed with L-tyrosine as starting material. The new DOPA analogue could be used in building bioactive compounds.

Key Words: Bioactive compound, L-DOPA analogue, Synthesis, L-Tyrosine.

DOPA and its analogues have been useful unit in many biologically active natural products, such as the inhibitor of FPTase, pepticcinnamin E¹, OF4949-I² (Fig. 1).

Fig. 1

Many methods have been reported for preparation of DOPA analogue³, such as traditional Schollkopf method for preparation of chiral amino acid; the improved synthesis of selectively protected L-DOPA derivatives from L-tyrosine, *via* Reimer-Tiemann to obtain compound **5** and Dakin reaction and Baeyer-Villiger oxidation to obtain selectively O-benylation L-DOPA derivatives **7** reported by Jung and Lazarova⁴ (Fig. 2):

In above procedure, the compound **5** was prepared according to Reimer-Tiemann process, such reaction had to run refluxing in solution of sodium hydroxide (6 equiv) in water and chloroform for 4 h, so risking in substantial racemization (15-20 %) according to the report of Boger⁵ even under the reaction conditions (2 equiv of K₂CO₃, acetone, 60 °C); furthermore, the O-benylation of tyrosine phenol in compound **5** also need vigorous reaction conditions (4.4 equiv of K₂CO₃,

Fig. 2

2/1 chloroform/methanol, reflux 4 h), which may cause racemization as well.

Wilcoxon⁶ reported an another synthetic method of O-benylation L-DOPA derivative from L-tyrosine based on the conditions described by Boger⁵ by utilizing warm conditions (2.5equiv of BnBr, 2.5equiv of K₂CO₃, 0.1 equiv of Et₄NI, DMF, 25 °C) to minimize possible racemization. However no efficient methods have been report to prepare O-methylated, N-methylated L-DOPA analogue even they are very useful building block for the total synthesis of many biological active natural compounds.

Herein, we reported an efficient method for synthesis O-methylation, N-methylation chlorinated L-DOPA derivative, which could be utilized as key intermediate in the total synthesis of natural products and their derivatives, such as analogues of pepticcinnamin E **1**. In our prior study of total synthesis of pepticcinnamin E, we obtained the novel DOPA analogue through catalytic hydrogenation of the dehydroamino acids (DDAA)⁷. In this paper, we report the other strategy to

obtain new DOPA analogue by starting from nature amino acid. We employed L-tyrosine as starting material *via* synthetic strategy based on Baeyer-Villiger oxidation, methylation under Coggins's condition⁸ and finally chlorination by Cl₂ gas in dichloromethane to give new DOPA analogue **16** (Fig. 3).

Fig. 3

Melting points were determined with an electrothermal digital melting point apparatus and were uncorrected. Optical rotation were recorded on a Perkin-Elmer Model 341 polarimeter, at the sodium D line. NMR and spectra were run either on Bruker-200 and Bruker-300 or on Varian-400.

Compound **9**, **10**, **11**^{9a}, **12**⁵, **13**¹⁰, **14**⁷, **15**¹¹ were prepared based on the procedures reported in literatures.

Preparation of L-N-methyl-3-hydroxy-4-methoxy-6-chlorophenylalanine methyl ester **16**: To a stirred solution of compound **15** (0.24 g, 1 mmol) in dichloromethane was bubbled chlorine at 0 °C until **15** was converted completed showed by TLC plate. The yellow reaction solution was concentrated at 0 °C to give slight yellow oil, which was chromatographed to yield final product **16** as pale yellow oil, 107 mg, yield 39.1 %. ¹H NMR (CDCl₃, 400 Hz) δ ppm: 6.82 (s, 1H, Ar-H), 6.79(s, 1H, Ar-H), 3.85(s, 3H, COOMe), 3.68 (s, 3H, OMe), 3.63-3.48 (m, 1H, CH), 3.05-2.93 (m, 2H, CH₂), 2.39 (s, 3H, NMe).

REFERENCES

- (a) S. Omura and H. Tomoda, *Pure Appl. Chem.*, **66**, 2267 (1994); (b) S. Omura, D.V. der Pyl, J. Inokoshi, Y. Takahashi and H. Takeshima, *J. Antibiot. (Tokyo)*, **46**, 222 (1993); (c) K. Shiomi, H. Yang, J. Inokoshi, D. Van der Pyl, A. Nakagawa, H. Takeshima and S. Omura, *J. Antibiot. (Tokyo)*, **46**, 229 (1993).
- L. Ciasullo, A. Casapullo, A. Cutignano, G. Bifulco, C. Debitus, J. Hooper, L. Gomez-Paloma and R. Riccio, *J. Nat. Prod.*, **65**, 407 (2002).
- (a) J.F. Siuda, *J. Org. Chem.*, **40**, 3611 (1975); (b) M. Kawai, M. Chorew, J.M. Rose and M. Goodman, *J. Med. Chem.*, **23**, 420 (1980).
- M.E. Jung and T.I. Lazarova, *J. Org. Chem.*, **62**, 1553 (1997).
- D.L. Boger and D. Yohannes, *J. Org. Chem.*, **52**, 5283 (1987).
- C. Chen Y.F. Zhu and K. Wilcoxon, *J. Org. Chem.*, **65**, 2574 (2000).
- D.Q. Sun, *Turk. J. Chem.*, **34**, 181 (2010).
- J.R. Coggins and N.L. Benoiton, *Can. J. Chem.*, **49**, 1968 (1971).
- (a) Y.L. Song, M.L. Peach, P.P. Roller, S. Qiu, S.M. Wang and Y.Q. Long, *J. Med. Chem.*, **49**, 1585 (2006); (b) M.R. Heinrich and W. Steglich, *Tetrahedron*, **59**, 9231 (2003).
- S. Kobayashi, H. Tanaka, H. Amii and K. Uneyama, *Tetrahedron*, **59**, 1547 (2003).
- R.J. Chen, D.G. Zhu, Z.Q. Hu, Z.M. Zheng and X.C. Chen, *Tetrahedron: Asymm.*, **21**, 39 (2010).